Growing evidence supports the role of Impella in the prevention of acute kidney injury in high-risk percutaneous interventions (HR-PCIs). The Mehran contrast-induced nephropathy risk score may serve as a helpful risk stratification tool in discerning patients undergoing HR-PCI who may benefit from renal protection with Impella support. Further research is warranted to validate this renal protection strategy.
© 2020 Wiley Periodicals, Inc.